Gemini Therapeutics (GMTX) Insider Trading & Ownership $64.96 +1.45 (+2.28%) (As of 11/22/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends Gemini Therapeutics (NASDAQ:GMTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage12.90%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$972,546.33Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$47,025.00 Get GMTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Gemini Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address GMTX Insider Buying and Selling by Quarter Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Gemini Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/26/2022Braden Michael LeonardMajor ShareholderSell22,500$2.09$47,025.00 4/13/2022Braden Michael LeonardMajor ShareholderBuy191,769$1.52$291,488.88 4/11/2022Braden Michael LeonardMajor ShareholderBuy504,487$1.35$681,057.45 (Data available from 1/1/2013 forward) GMTX Insider Trading Activity - Frequently Asked Questions Who is on Gemini Therapeutics's Insider Roster? The list of insiders at Gemini Therapeutics includes Braden Michael Leonard. Learn more on insiders at GMTX. What percentage of Gemini Therapeutics stock is owned by insiders? 12.90% of Gemini Therapeutics stock is owned by insiders. Learn more on GMTX's insider holdings. Gemini Therapeutics Key ExecutivesDr. Georges Gemayel C.F.A. (Age 62)Ph.D., Interim Pres & CEO and Exec. Chairperson Compensation: $256.73kMr. Brian Piekos (Age 46)Chief Bus. Officer, CFO, Principal Accounting & Principal Financial Officer Compensation: $549.73kMr. Jason Patrick Meyenburg M.B.A. (Age 44)M.D., Advisor Compensation: $715.96kMr. Patrick Truesdell (Age 41)VP of Fin. & Controller More Insider Trading Tools from MarketBeat Related Companies Catalent Insider Selling Sarepta Therapeutics Insider Selling Revolution Medicines Insider Selling Intra-Cellular Therapies Insider Selling Roivant Sciences Insider Selling Elanco Animal Health Insider Selling Blueprint Medicines Insider Selling Lantheus Insider Selling Nuvalent Insider Selling Viking Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:GMTX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
